TrialBMC health services research2019

Cost-utility analysis of palonosetron in the antiemetic regimen for cisplatin-containing highly emetogenic chemotherapy in Japan.

Munenobu Kashiwa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.